Proteomics Market Regional Analysis:
North American Market Insights
The proteomics market in North America is poised to dominate 43% revenue share by 2035. The market for proteomics products is growing as bispecific antibody conjugates and protein therapies become more widely available in North America for the purpose of treating and diagnosing diseases. Ten ADCs have already achieved FDA approval in the US, while over 90 ADCs are undergoing clinical development worldwide. A number of clinical indications that recently received approval for recombinant protein therapy include cancer, autoimmunity/inflammation, exposure to infectious agents, and hereditary illnesses. Proteomics is finding widespread use in antibody-drug conjugates and protein therapies in North America, which is driving up demand for proteomics products and propelling the market's quick expansion.
Europe Market Insights
The Europe proteomics market is anticipated to grow at a significant growth rate during the forecast period. The demand for the market is boosted by technical improvements, government support for proteomics, and Europe's growing research and expenditure. The rising prevalence of chronic illnesses like cancer, heart disease, respiratory conditions, and other conditions is also driving up market growth in Europe. The World Health Organization estimates that 60 million people in the European Region or 10.3% of men and 9.6% of women over the age of 25 have diabetes. Diabetes is growing more common in the European Region throughout all age groups, mainly due to increases in overweight and obesity, poor diets, and inactivity. These proteomics benefits are propelling the industry ahead.
